New drug lets PKU patients eat more protein – but lifelong treatment still needed

NCT ID NCT04404530

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jan 16, 2026 · Last updated May 15, 2026 · Updated 19 times

Summary

This study looks at how Palynziq, a medication for phenylketonuria (PKU), improves diet, brain function, and nutrition. PKU is a genetic disorder that makes it hard to break down an amino acid called phenylalanine, which can build up and cause brain damage. The study will follow 45 adults who are already taking Palynziq to see if they can eat more natural protein and feel better, but they must stay on the drug for life to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHENYLKETONURIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Emory University Hospital Georgia Clinical Research Center
RECRUITING

Atlanta, Georgia, 30322, United States
The Emory Clinic
RECRUITING

Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.

PHENYLKETONURIAS